Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - Deutsche Bank (ETR:DBKGn) has lowered its price target on Gerresheimer AG (BS:GXId) (ETR:GXI) (OTC:GRRMF) to EUR55.00 from EUR58.00 while maintaining a Hold rating on the stock.
The price target reduction comes just five weeks after Gerresheimer’s previous guidance cut, with the company again slightly reducing its outlook on Thursday.
Deutsche Bank cited limited visibility regarding the required acceleration in the second half of the year, raising concerns about Gerresheimer’s ability to meet its current guidance.
The bank specifically pointed to ongoing challenges in Gerresheimer’s cosmetics business and continued destocking in oral liquid containers, with no clear timeline for recovery in these problem areas.
Deutsche Bank also expressed skepticism about Gerresheimer’s new medium-term guidance of 6-9% organic sales growth, describing it as "ambitious" and noting that the company’s 2024 guidance remains heavily weighted toward the second half of the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.